Anson Funds Management LP Acquires New Position in Apricus Biosciences, Inc (APRI)

Anson Funds Management LP acquired a new stake in shares of Apricus Biosciences, Inc (NASDAQ:APRI) during the third quarter, Holdings Channel reports. The institutional investor acquired 5,092,580 shares of the company’s stock, valued at approximately $1,723,000. Apricus Biosciences comprises 0.4% of Anson Funds Management LP’s holdings, making the stock its 21st largest position. Anson Funds Management LP owned 0.66% of Apricus Biosciences as of its most recent filing with the SEC.

Apricus Biosciences, Inc (NASDAQ:APRI) traded down 2.19% during trading on Monday, reaching $2.68. 209,690 shares of the company’s stock were exchanged. Apricus Biosciences, Inc has a 52 week low of $1.10 and a 52 week high of $15.40. The stock’s market capitalization is $20.72 million. The company’s 50 day moving average price is $2.01 and its 200-day moving average price is $1.15.

This story was first published by sleekmoney and is the property of of sleekmoney. If you are accessing this story on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this story can be accessed at

Separately, Zacks Investment Research raised shares of Apricus Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 18th.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

5 Day Chart for NASDAQ:APRI

Want to see what other hedge funds are holding APRI? Visit to get the latest 13F filings and insider trades for Apricus Biosciences, Inc (NASDAQ:APRI).

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *